For a global health company, we evaluated the expected incremental cost-effectiveness of one of their products. The cost-effectiveness outcome was needed to support adjuvant therapy decision making versus current clinical practice in the Netherlands. We… developed a Markov model to project distant recurrences survival, quality-adjusted life expectancy and direct medical costs over a time horizon of 30 years.